Investment Rating - The industry investment rating is optimistic (maintained) [1] Core Insights - Boston Scientific is a leading global medical device platform company with over 40 years of development, featuring eight major segments including electrophysiology, left atrial appendage closure, cardiac intervention, peripheral intervention, rhythm management, endoscopy, urology, and neuromodulation, with significant market shares in left atrial appendage closure, endoscopy, and urology/women's health [3] - The company's diverse product offerings in various segments are expected to continue growing at a rate higher than the market average, serving as a core driver for revenue growth [3] Summary by Sections Cardiac Intervention - The cardiac intervention business encompasses drug-eluting therapies, complex PCI treatments, and PCI intraoperative navigation, with a total addressable market of approximately $8 billion in 2023 and a projected growth rate of high single digits [10][59] - The drug-eluting therapy segment is a key focus, with the latest product, Synergy, expected to capture a 21% global market share by 2025 [12] - The AGENT drug-coated balloon is the first and only FDA-approved device for treating in-stent restenosis in the U.S., with a projected market of $500 million [23][25] Peripheral Intervention - The peripheral intervention business is projected to have a total addressable market of approximately $9 billion in 2023, with growth rates of 5% to 13% across various treatment areas [58][59] - TheraSphere, the first FDA-approved radioactive embolization technique for treating unresectable hepatocellular carcinoma, is expected to expand its market from $500 million to over $3.5 billion in the next decade [63][65] Urology - Boston Scientific is a market leader in the single-use ureteroscope market, with revenue growth exceeding the industry average, supported by innovations such as renal pressure monitoring [3] Neuromodulation - The neuromodulation segment features a rich product portfolio, including deep brain stimulation devices with significant market potential, projected to reach $2.5 billion [3] Endoscopy - The company is focusing on the single-use endoscope market, with advanced and highly differentiated products, anticipating a market potential of approximately $4.8 billion [3] Rhythm Management - The rhythm management segment is transitioning towards high-value markets, with innovative products such as leadless pacemakers expected to gain FDA approval by 2026 [3]